Augmentin '125' and Eosinophilia - a phase IV clinical study of FDA data

Summary:

Eosinophilia is reported as a side effect among people who take Augmentin '125' (amoxicillin; clavulanate potassium), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Nexium, and have Bronchitis.

The phase IV clinical study analyzes which people have Eosinophilia when taking Augmentin '125'. It is created by eHealthMe based on reports of 10,373 people who have side effects when taking Augmentin '125' from the FDA, and is updated regularly.

What is Augmentin '125'?

Augmentin '125' has active ingredients of amoxicillin; clavulanate potassium. It is often used in sinusitis. eHealthMe is studying from 10,452 Augmentin '125' users. Check the latest studies of Augmentin '125'.

What is Eosinophilia?

Eosinophilia (eosinophil count in the peripheral blood exceeds) is found to be associated with 956 drugs and 1,392 conditions by eHealthMe. Check the latest studies of Eosinophilia.

On Jul, 13, 2026

10,373 people reported to have side effects when taking Augmentin '125'.
Among them, 154 people (1.48%) have Eosinophilia.

Could Augmentin '125' cause Eosinophilia?

Among these 154 people:

How long have people been on Augmentin '125' when they have Eosinophilia? *

Click here to view more results

What is the gender of people who have Eosinophilia when taking Augmentin '125'? *

Click here to view

* Approximation only. Some reports may have incomplete information.

Do you take Augmentin '125' and have Eosinophilia?

- Check whether Eosinophilia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Augmentin '125':

Augmentin '125' (10,452 reports)

Eosinophilia treatments and more:

Eosinophilia (20,276 reports)

How severe was Eosinophilia and when was it recovered:

Eosinophilia in Augmentin '125'

Expand to all the drugs that have ingredients of amoxicillin; clavulanate potassium:

Eosinophilia and drugs with ingredients of amoxicillin; clavulanate potassium (540 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Augmentin '125':

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Eosinophilia:

Eosinophilia (956 drugs)

Browse all the conditions that are associated with Eosinophilia:

Eosinophilia (1,392 conditions)

Related publications that referenced our studies

Azuma N, Matsui K, Hashimoto N, Yoshikawa T, Sano H, "Successful Switch to Golimumab for Eosinophilia and Skin Symptoms Related to Multiple Biologics in a Patient with Rheumatoid Arthritis", Internal Medicine, 2017 Jun .
Chiriac A, Brzezinski P, Stolnicu S, Podoleanu C, Moldovan C, Molnar C, Taranu T, "Eosinophilia–A rare possible adverse reaction during anti-tumor necrosis factor-alpha therapy for psoriasis", Journal of Dermatological Treatment, 2016 Mar .
Guidelli GM, Tenti S, Fioravanti A, "Severe eosinophilia during anti-tumor necrosis factor-alpha therapy for psoriatic arthritis", Indian Journal of Dermatology, Venereology, and Leprology, 2015 Jan .
Malisiewicz B, Murer C, Schmid JP, French LE, Schmid-Grendelmeier P, Navarini AA, "Eosinophilia during psoriasis treatment with TNF antagonists", Dermatology, 2013 Jan .
Azuma N, Matsui K, Hashimoto N, Yoshikawa T, Sano H, "Successful Switch to Golimumab for Eosinophilia and Skin Symptoms Related to Multiple Biologics in a Patient with Rheumatoid Arthritis", Internal Medicine, 2017 Jun .
Chiriac A, Brzezinski P, Stolnicu S, Podoleanu C, Moldovan C, Molnar C, Taranu T, "Eosinophilia–A rare possible adverse reaction during anti-tumor necrosis factor-alpha therapy for psoriasis", Journal of Dermatological Treatment, 2016 Mar .
Guidelli GM, Tenti S, Fioravanti A, "Severe eosinophilia during anti-tumor necrosis factor-alpha therapy for psoriatic arthritis", Indian Journal of Dermatology, Venereology, and Leprology, 2015 Jan .
Malisiewicz B, Murer C, Schmid JP, French LE, Schmid-Grendelmeier P, Navarini AA, "Eosinophilia during psoriasis treatment with TNF antagonists", Dermatology, 2013 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on amoxicillin; clavulanate potassium (the active ingredients of Augmentin '125') and Augmentin '125' (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.